For the past three years, a cohort of high-flying startups has pitched a compelling story to investors: Electronic Health Records (EHRs) are terrible to use, and our AI will fix them. It was a winning argument, minting unicorns like Abridge and Ambience Healthcare. But this week, the industry’s dominant player stopped ignoring the competition and made its move.
The News
Epic, the dominant EHR vendor in the United States, officially rolled out its own native ambient AI charting tool this week. The new feature listens to patient-doctor conversations during appointments, drafts clinical documentation in real-time, and even prepares orders based on the dialogue. Unlike previous integrations that required third-party “add-ons,” this capability is now built directly into the core workflow of the system used by organizations holding 42% of the acute care market share. The timing is particularly pointed, coming just days after the highly regarded KLAS research group crowned startup Abridge as the leader in the ambient scribe category. Epic’s move effectively asks health systems: why pay extra for the “best” third-party tool when a “good enough” one is already inside the software you pay millions for?
Why It Matters
This is the classic “platform vs. product” battle, but with life-and-death stakes. For hospital CIOs, the appeal of a native tool is massive as there are no separate security reviews, no complex integrations to manage, and likely lower costs compared to contracting with a separate vendor. If Epic’s tool works reliably, it transforms ambient documentation from a premium pilot project into a default utility, democratizing access to burnout-reducing technology for hundreds of thousands of clinicians who might never have convinced their hospital administration to buy a standalone product.
This launch also underscores Epic’s aggressive defense of its territory. The company is already embroiled in an antitrust lawsuit with Particle Health over allegations of stifling competition in the payer platform market. By bundling a scribe directly into the EHR, Epic is making it exponentially harder for any outside vendor to “justify their existence,” as MedCity News put it.
The Skeptic’s View
However, “good enough” might not cut it in high-stakes medicine. Competitors are already pivoting their arguments to emphasize specialization and workflow depth. DeepScribe CEO Matthew Ko argues that a generalist tool built by an EHR vendor can’t match the nuanced support needed in complex fields like oncology or cardiology, noting that “differentiation isn’t simply whether a note can be generated.” Heidi Health CEO Tom Kelly echoes this, arguing that while Epic focuses on structured data entry, startups are building broader “operating systems” that reduce cognitive burden beyond just typing notes. There is also a significant trust gap; startups have spent years building interfaces that clinicians actually like, and if the native tool produces notes that are clunky or hallucinate frequently, doctors will switch it off immediately regardless of the convenient integration.
Looking Ahead
The next six months will be a brutal proving ground. Watch the adoption numbers in complex specialties versus primary care. If oncologists and cardiologists stick with third-party tools while family medicine practitioners switch to Epic’s native offering, we might see a bifurcated market where startups survive only as premium tools for specialists. But if the native tool proves capable across the board, the group of AI scribe unicorns might face a very difficult path.